Mira Pharmaceuticals (MIRA) Receivables (2023 - 2024)
Mira Pharmaceuticals (MIRA) posted Receivables of $40439.0 for Q4 2024, up 139.82% sequentially from $16862.0 in Q4 2023, and up 139.82% YoY from $16862.0 in Q1 2024.
Mira Pharmaceuticals (MIRA) Receivables (2023 - 2024) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Receivables data on file, last reported at $40439.0 in Q4 2024.
- Quarterly Receivables rose 139.82% year-over-year to $40439.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $40439.0 (up 139.82% YoY) and the FY2024 annual result came in at $40439.0, up 139.82% from the prior year.
- Receivables climbed to $40439.0 in Q4 2024 per MIRA's latest filing, from $16862.0 in the prior quarter.
- The five-year high for Receivables was $40439.0 in Q4 2024, with the low at $16862.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 21.18 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 17.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 12.48 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 40,439.00 |
| Dec 31, 2023 | 16,862.00 |